[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343590-105":59,"doc-detail-343590-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","efficacy-and-safety-of-natural-killer-cell-therapy-in-patients-with-solid-tumors-a-systematic-review-and-meta-analysis","Efﬁcacy and safety of natural killer cell therapy in patients with solid tumors - a systematic review and meta-analysis","","Meta-analysis evaluating the clinical efficacy and safety of unmodified natural killer (NK) cell therapies for patients with solid tumors. Studies were searched in PubMed, Embase, Cochrane, and ClinicalTrials.gov up to May 2024. Thirty-one trials with 600 patients across multiple cancer types assessed objective response rates (ORR). NK therapies showed promising ORRs, including 72.3% in hepatocellular carcinoma, and reported favorable safety, with fatigue as the most common adverse event. Further research is recommended to optimize integration into standard regimens.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-natural-killer-cell-therapy-in-patients-with-solid-tumors-a-systematic-review-and-meta-analysis/343590/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-natural-killer-cell-therapy-in-patients-with-solid-tumors-a-systematic-review-and-meta-analysis/343590.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What therapy does this systematic review evaluate for solid tumors?","Question",{"text":113,"@type":114},"It assesses the clinical efficacy and safety of unmodified natural killer (NK) cell therapies in patients with solid tumors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the studies selected and up to what date?",{"text":118,"@type":114},"The review systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov up to May 2024.",{"name":120,"@type":111,"acceptedAnswer":121},"What outcomes and safety findings were reported?",{"text":122,"@type":114},"The analysis focused on objective response rates (ORR). Safety was favorable overall, with fatigue reported as the most common adverse event.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343590,1790211369,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Systematic Review PUBLISHED 16 October 2024  \nDOI 10.3389/fimmu.2024.1454427  \nOPEN ACCESS  \nEDITED BY  \nMassimiliano Petrini,  \nScientiﬁc Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy  \nREVIEWED BY  \nYuan Tian,  \nAfﬁliated Hospital of Shandong University of Traditional Chinese Medicine, China Hiroshi Terunuma,  \nBiotherapy Institute of Japan, Inc., Japan Yanlin Yu,  \nNational Institutes of Health (NIH), United States  \n*CORRESPONDENCE  \nHyeonwoo Yim  \n [y1693@catholic.ac.kr](y1693@catholic.ac.kr)  \nRECEIVED 25 June 2024  \nACCEPTED 23 September 2024  \nPUBLISHED 16 October 2024  \nCITATION  \nPark H, Kim G, Kim N, Ha S and Yim H (2024) Efﬁcacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis.  \nFront. Immunol. 15:1454427 .  \ndoi: 10.3389/fimmu.2024.1454427  \nCOPYRIGHT  \n© 2024 Park, Kim, Kim, Ha and Yim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEfﬁcacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis  \nHeesook Park 1, Gyurin Kim 1, Najin Kim 2, Sungyoen Ha 3 and Hyeonwoo Yim 4*  \n1 Department of Public Health, The Catholic University of Korea, Seoul, Republic of Korea, 2 Medical Library, The Catholic University of Korea, Seoul, Republic of Korea, 3 Department of Statistics, Sungkyunkwan University of Korea, Seoul, Republic of Korea, 4 Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea  \nIntroduction: In 2020, global cancer statistics reported 19 .3 million new cases and 10 million deaths annually, highlighting the urgent need for effective treatments. Current therapies, such as surgery, radiation, and chemotherapy, have limitations in comprehensively addressing solid tumor. Recent advances in cancer biology and immuno-oncology, including CAR-T cell therapy, show promise but face efﬁcacy challenges against solid tumors.  \nMethods: This meta-analysis systematically reviewed studies from PubMed, Embase, Cochrane, and [ClinicalTrials.gov](ClinicalTrials.gov) databases up to May 2024 to evaluate the clinical efﬁcacy and safety of unmodiﬁed NK cell therapies in solid tumors. The included trials focused on reporting objective response rates (ORR) .  \nResults: Thirty-one trials involving 600 patients across various cancers (e. g., NSCLC, HCC, breast, ovarian) were analyzed. NK cell therapies demonstrated promising ORRs, particularly 72.3% in hepatocellular carcinoma, often in combination with local therapies. Safety proﬁles were favorable, with fatigue being the most common adverse event.  \nDiscussion: NK cell therapies represent a promising treatment option for solid tumors, offering a viable alternative to genetically modiﬁed cell therapies like CAR-T. Further research is needed to optimize the clinical utility of NK cell therapy and integrate it effectively into standard cancer treatment regimens.  \nSystematic review registration: [https://www.crd.york.ac.uk/prospero/display_](https://www.crd.york.ac.uk/prospero/display_)[record.php?ID=CRD42023438410](record.php?ID=CRD42023438410), [identi](identi)ﬁ[er CRD42023438410](er CRD42023438410) .  \nKEYWORDS  \nkiller cells, natural, NK cells, neoplasms, review, systematic, meta-analysis  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIntroduction  \nAccording to the Global Cancer Statistics of 2020, 19.3 million new cases of cancer are diagnosed annually worldwide, with 10 million individuals succumbing to the disease. The most prevalent cancer types includ","cbCaimtHXjhfEPa3","https://ap.wps.com/l/cbCaimtHXjhfEPa3","pdf",3497967,"English","# Introduction\n# Methods\n# Results\n# Discussion\n# Systematic review registration\n# Keywords","[{\"question\":\"What therapy does this systematic review evaluate for solid tumors?\",\"answer\":\"It assesses the clinical efficacy and safety of unmodified natural killer (NK) cell therapies in patients with solid tumors.\"},{\"question\":\"How were the studies selected and up to what date?\",\"answer\":\"The review systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov up to May 2024.\"},{\"question\":\"What outcomes and safety findings were reported?\",\"answer\":\"The analysis focused on objective response rates (ORR). Safety was favorable overall, with fatigue reported as the most common adverse event.\"}]","Efﬁcacy and safety of natural killer cell therapy in patients with solid tumors - a systematic review and meta-analysis | PDF",1790051511,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65d6928e1fdc4cf5dd22ed5d771adcdb.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70f9d17fc2fa1ff2158b6fbf4c9d5d91.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a534e218f3c7c9727d73cd78d466bae.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d25f4425f69dc7c190cadd2dbc17fca.webp",980,1385]